John Renger - Oct 4, 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: Chief Scientific Officer
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol: CERE
Transactions as of: Oct 4, 2022
Transactions value $: -$560,922
Form type: 4
Date filed: 10/6/2022, 04:59 PM
Previous filing: Aug 12, 2022
Next filing: Nov 3, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$35.1K	+10K	+370.49%	$3.50^*	12.7K	Oct 4, 2022	Direct	F1
transaction	CERE	Common Stock	Options Exercise	$154K	+15K	+117.76%	$10.28	27.7K	Oct 4, 2022	Direct	F1
transaction	CERE	Common Stock	Sale	-$750K	-25K	-90.24%	$30.00	2.7K	Oct 4, 2022	Direct	F1

Showing 1 to 3 of 3 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-10K	-12.5%	$0.00	70.1K	Oct 4, 2022	Common Stock	10K	$3.50	Direct	F1, F2
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-15K	-11.1%	$0.00	120K	Oct 4, 2022	Common Stock	15K	$10.28	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2	25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.